

Step Therapy Criteria Proposal

Drug/Drug Class: **SSRI Step Therapy Edit**
 Implementation Date: **October 26, 2005**
 Prepared for:
 Prepared by: **Missouri Medicaid**

☐ New Criteria

☒ Revision of Existing Criteria

Executive Summary

Purpose: Ensure appropriate utilization of the Selective Serotonin Reuptake Inhibitors (SSRIs).

Why was this Issue Selected: Selective Serotonin Reuptake Inhibitor (SSRI) prescription claims accounted for 749,396 prescription drug claims, totaling \$56,511,508, for the time period January 1, 2004 thru December 31, 2004. SSRI claims represent 4.8% of the total prescription benefit expenditures for Missouri Medicaid.

Program-specific information:	Drug		
	Drug	Claims	Expenses
	• Prozac®	3,518	\$335,189
	• Paxil®	4,758	\$450,099
	• Paxil CR®	50,799	\$4,923,304
	• Pexeva®	39	\$2,532
	• Celexa®	75,044	\$6,323,775
	• Zoloft®	212,716	\$20,186,883
	• Lexapro	174,424	\$12,527,697
	• Luvox	8	\$377
	• Paroxetine	93,326	\$7,385,074
	• Citalopram	7,140	\$346,680
	• Fluoxetine	117,547	\$3,286,131
	• Fluvoxamine	<u>10,069</u>	<u>\$743,051</u>
	Totals	749,396	\$56,511,508

Setting & Population: Utilization in patients with diagnosis of depression.

Type of Criteria:

<input type="checkbox"/> Increased risk of ADE	<input checked="" type="checkbox"/> Non-Preferred Agent
<input checked="" type="checkbox"/> Effectiveness	<input type="checkbox"/>

Data Sources: ☐ Only administrative
databases

☒ Databases + Prescriber-
supplied

Setting & Population

- Drug Class for review: Selective Serotonin Reuptake Inhibitors (SSRIs)
- Age range: All ages
- Gender: Male and female

Approval Criteria

Reference Products: Fluoxetine and Citalopram

- Documented compliance on current non-reference therapy
- Document ADE/ADR to reference products
- Documented adequate initial therapeutic intervention with 1 or more reference products

Denial Criteria

- Greater than 2 SSRI chemical agents prescribed concurrently for more than 90 days.
- Lack of compliance to non-reference SSRI therapy
- Lack of adequate initial therapeutic intervention with reference product(s)

Required Documentation

Laboratory results: ☐
MedWatch form: ☐

Progress notes: ☐

Disposition of Edit

- **Denial:** Edit 681 "Step Therapy"

References

1. Cyberformance v2.02, "FDB - Business PlanFormance- 05/05 publication, ACS-Heritage Inc. May 2005.
2. Facts and Comparisons, p.918 – 928c; 2005.
3. USPDI, Micromedex, 2005.

